journal
MENU ▼
Read by QxMD icon Read
search

Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research

journal
https://read.qxmd.com/read/30711074/response-to-letter-to-the-editor-related-to-the-retraction-of-a-trial-included-in-a-meta-analysis-of-interventions-to-enhance-oral-medication-adherence-titled-effectiveness-and-content-analysis-of-interventions-to-enhance-oral-antidiabetic-drug-adherence-in
#1
LETTER
Hervé Tchala Vignon Zomahoun, Marijn de Bruin, Laurence Guillaumie, Jocelyne Moisan, Jean-Pierre Grégoire, Line Guénette, Norma Pérez, Lydi-Anne Vézina-Im
No abstract text is available yet for this article.
February 2019: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://read.qxmd.com/read/30711073/the-retraction-of-a-trial-included-in-a-meta-analysis-of-interventions-to-enhance-oral-medication-adherence
#2
LETTER
Richard Gray, Amal Al-Ghareeb, Jenny Davis, Lisa McKenna, Stav Amichai Hillel
No abstract text is available yet for this article.
February 2019: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://read.qxmd.com/read/30711072/economic-evaluation-of-stem-cell-therapies-in-neurological-diseases-a-systematic-review
#3
REVIEW
Anjali Nagpal, Rachel Milte, Susan W Kim, Susan Hillier, Monica A Hamilton-Bruce, Julie Ratcliffe, Simon A Koblar
OBJECTIVES: To examine economic evaluation studies of stem cell therapies (SCTs) in neurological disorders and to provide an overview of the quality of the economic evidence available on this topic. METHODS: The review examined studies that performed an economic evaluation of the use of stem cells in adult patients with neurological diseases and that were published in English during the period 2007 to 2017. Data analyzed and reported included study population, disease indication, main analytical approaches for the economic analysis and perspective, key assumptions made or tested in sensitivity analyses, cost outcomes, estimates of incremental cost effectiveness, and approaches to quantifying decision uncertainty...
February 2019: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://read.qxmd.com/read/30711071/equity-weights-for-socioeconomic-position-two-methods-survey-of-stated-preferences-and-epidemiological-data
#4
Anita Lal, Mohammadreza Mohebi, Rohan Sweeney, Marjory Moodie, Anna Peeters, Rob Carter
BACKGROUND: There is an implicit equity approach in cost-effectiveness analysis that values health gains of socioeconomic position groups equally. An alternative approach is to integrate equity by weighting quality-adjusted life-years according to the socioeconomic position group. OBJECTIVES: To use two approaches to derive equity weights for use in cost-effectiveness analysis in Australia, in contexts in which the use of the traditional nonweighted quality-adjusted life-years could increase health inequalities between already disadvantaged groups...
February 2019: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://read.qxmd.com/read/30711070/estimating-chu-9d-utility-scores-from-the-waite-a-mapping-algorithm-for-economic-evaluation
#5
Tomos Robinson, Yemi Oluboyede
BACKGROUND: The Weight-Specific Adolescent Instrument for Economic Evaluation (WAItE) is a new condition-specific patient reported outcome measure that incorporates the views of adolescents in assessing the impact of above healthy weight status on key aspects of their lives. Presently it is not possible to use the WAItE to calculate quality adjusted life years (QALYs) for cost-utility analysis (CUA), given that utility scores are not available for health states described by the WAItE...
February 2019: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://read.qxmd.com/read/30711069/association-between-disability-cognition-fatigue-eq-5d-3l-domains-and-utilities-estimated-with-different-western-european-value-sets-in-patients-with-multiple-sclerosis
#6
Jennifer Eriksson, Gisela Kobelt, Mia Gannedahl, Jenny Berg
OBJECTIVES: To assess the association between fatigue, cognition, domains of the EuroQol five-dimensional questionnaire (EQ-5D-3L), disability, and utilities estimated with several Western European value sets in patients with multiple sclerosis (MS). METHODS: Data from a multinational, cross-sectional, observational study of patients with MS (N = 16,808) conducted in 16 European countries were used. Health-related quality of life data were collected through the EQ-5D-3L, and fatigue and cognitive difficulties were self-assessed on a 10-point visual analogue scale...
February 2019: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://read.qxmd.com/read/30711068/perceptions-of-response-burden-associated-with-completion-of-patient-reported-outcome-assessments-in-oncology
#7
Thomas M Atkinson, Carolyn E Schwartz, Leah Goldstein, Iliana Garcia, Daniel F Storfer, Yuelin Li, Jie Zhang, Bernard H Bochner, Bruce D Rapkin
BACKGROUND: Patient response burden is often raised as a human subject concern in consideration of the length or complexity of patient-reported outcome (PRO) instruments used in oncology. OBJECTIVES: To quantify patient response burden and identify its predictive factors. METHODS: Data were collected presurgically during a prospective trial that used a comprehensive symptom and health-related quality-of-life (HRQOL) PRO assessment. A subset of patients also completed HRQOL interviews...
February 2019: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://read.qxmd.com/read/30711067/was-it-worth-introducing-health-economic-evaluation-of-innovative-drugs-in-the-french-regulatory-setting-the-case-of-new-hepatitis-c-drugs
#8
Valérie Clément, Véronique Raimond
OBJECTIVE: This paper constitutes the first attempt to draw lessons from the recent uptake of health economic evaluation of innovative drugs in the French regulatory framework. STUDY DESIGN: Taking the example of new direct-acting antivirals against hepatitis C virus, the paper asks whether and how the cost-effectiveness (CE) opinions issued by the French National Health Authority improve the information available to support the pricing decisions. METHODS: The analysis compares the assessment of these drugs based on three different sources: CE opinions, clinical opinions, and the published cost-utility analyses (CUA) available in the literature and identified through a systematic review...
February 2019: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://read.qxmd.com/read/30711066/comparison-of-recommendations-and-use-of-cardiovascular-risk-equations-by-health-technology-assessment-agencies-and-clinical-guidelines
#9
Marissa Blieden Betts, Sandra Milev, Meredith Hoog, Hyosung Jung, Dušan Milenković, Yi Qian, Ming-Hui Tai, Lucie Kutikova, Guillermo Villa, Christine Edwards
OBJECTIVES: To identify risk equations for cardiovascular diseases (CVDs) in primary and secondary prevention settings that are used or recommended by health technology assessment (HTA) organizations and in clinical guidelines (CGs). METHODS: A targeted literature review was conducted using a two-stage search strategy. First, HTA reviews of manufacturers' drug submissions, reports from established HTA organizations (Europe, Canada, and Australia), and CGs from countries with and without HTA organizations, including the United States, were identified...
February 2019: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://read.qxmd.com/read/30711065/a-review-of-patient-reported-outcomes-labeling-for-oncology-drugs-approved-by-the-fda-and-the-ema-2012-2016
#10
Ari Gnanasakthy, Amy Barrett, Emily Evans, Denise D'Alessio, Carla DeMuro Romano
OBJECTIVES: To compare US Food and Drug Administration (FDA) and European Medicines Agency (EMA) labeling for evidence based on patient-reported outcomes (PROs) of new oncology treatments approved by both agencies. METHODS: Oncology drugs and indications approved between 2012 and 2016 by both the FDA and the EMA were identified. PRO-related language and analysis reported in US product labels and drug approval packages and EMA summaries of product characteristics were compared for each indication...
February 2019: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://read.qxmd.com/read/30711064/the-cost-effectiveness-of-financial-incentives-for-viral-suppression-hptn-065-study
#11
Blythe Adamson, Wafaa El-Sadr, Dobromir Dimitrov, Theresa Gamble, Geetha Beauchamp, Josh J Carlson, Louis Garrison, Deborah Donnell
OBJECTIVE: To evaluate the cost-effectiveness of financial incentives for human immunodeficiency virus (HIV) viral suppression compared to standard of care. STUDY DESIGN: Mathematical model of 2-year intervention offering financial incentives ($70 quarterly) for viral suppression (<400 copies/ml3 ) based on the HPTN 065 clinical trial with HIV patients in the Bronx, NY and Washington, D.C. METHODS: A disease progression model with HIV transmission risk equations was developed following guidelines from the Second Panel on Cost-Effectiveness in Health and Medicine...
February 2019: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://read.qxmd.com/read/30711063/assessing-the-cost-effectiveness-of-updated-breast-cancer-screening-guidelines-for-average-risk-women
#12
Ya-Chen Tina Shih, Wenli Dong, Ying Xu, Yu Shen
BACKGROUND: Several specialty societies have recently updated their breast cancer screening guidelines in late 2015/early 2016. OBJECTIVES: To evaluate the cost-effectiveness of US-based mammography screening guidelines. METHODS: We developed a microsimulation model to generate the natural history of invasive breast cancer and capture how screening and treatment modified the natural course of the disease. We used the model to assess the cost-effectiveness of screening strategies, including annual screening starting at the age of 40 years, biennial screening starting at the age of 50 years, and a hybrid strategy that begins screening at the age of 45 years and transitions to biennial screening at the age of 55 years, combined with three cessation ages: 75 years, 80 years, and no upper age limit...
February 2019: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://read.qxmd.com/read/30711062/paying-low-income-smokers-to-quit-the-cost-effectiveness-of-incentivizing-tobacco-quit-line-engagement-for-medicaid-recipients-who-smoke
#13
Marlon P Mundt, Timothy B Baker, David L Fraser, Stevens S Smith, Megan E Piper, Michael C Fiore
OBJECTIVES: To determine the cost-effectiveness of an incentive-based stop-smoking intervention that paid Medicaid recipients who smoke to take calls from a tobacco quit line. METHODS: A cost-effectiveness analysis was conducted alongside a randomized controlled trial. The analysis was conducted from a health care systems perspective on the basis of costs and effectiveness over a 6-month follow-up. Participants (n = 1900) were recruited from May 2013 to June 2015 through quit line (n = 980), clinic-based (n = 444), or community-based (n = 476) referrals...
February 2019: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://read.qxmd.com/read/30711061/cost-effectiveness-of-alemtuzumab-in-the-treatment-of-relapsing-forms-of-multiple-sclerosis-in-the-united-states
#14
Viktor Chirikov, Ingrid Ma, Namita Joshi, Dipen Patel, Alden Smith, Cindy Giambrone, Noelle Cornelio, Lobat Hashemi
OBJECTIVE: To evaluate the cost-effectiveness of alemtuzumab compared with fingolimod, natalizumab, ocrelizumab, and generic glatiramer acetate 20 mg among patients with relapsing multiple sclerosis (RMS) in the United States. STUDY DESIGN: Markov model with annual periods from payer perspective. METHODS: The modeled population represented pooled patients from the CARE-MS I and II trials. Therapies' comparative efficacy at reducing relapses and slowing disability worsening was obtained from network meta-analyses...
February 2019: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://read.qxmd.com/read/30711060/cost-utility-of-voretigene-neparvovec-for-biallelic-rpe65-mediated-inherited-retinal-disease
#15
Marita Zimmermann, Solomon J Lubinga, Reiner Banken, David Rind, Geri Cramer, Patricia G Synnott, Richard H Chapman, Sonya Khan, Josh Carlson
OBJECTIVE: The gene therapy voretigene neparvovec (VN) is the first Food and Drug Administration-approved treatment for vision loss owing to the ultra-rare RPE65-mediated inherited retinal disorders. We modeled the cost-utility of VN compared with standard of care (SoC). STUDY DESIGN: A 2-state Markov model, alive and dead, with a lifetime horizon. METHODS: Visual acuity (VA) and visual field (VF) were tracked to model quality-adjusted life-years (QALYs)...
February 2019: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://read.qxmd.com/read/30711059/the-internal-validity-of-discrete-choice-experiment-data-a-testing-tool-for-quantitative-assessments
#16
F Reed Johnson, Jui-Chen Yang, Shelby D Reed
OBJECTIVES: To develop a tool for testing internal validity of discrete choice experiment (DCE) data, deploy the program, and collect summary test results from a sample of active health researchers to demonstrate the practical utility of the tool in a wide range of health applications. METHODS: A previously developed Gauss program had been in use for testing internal validity. The program was translated to MATLAB and adapted, compiled, and deployed. Sixty-seven authors who had coauthored one or more published DCE studies between 2013 and 2016 were contacted by email; provided access to the tool, instructions, and an example data file; and invited to submit test summaries for tabulation...
February 2019: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://read.qxmd.com/read/30711058/methods-for-measuring-multiple-medication-adherence-a-systematic-review-report-of-the-ispor-medication-adherence-and-persistence-special-interest-group
#17
REVIEW
Priti P Pednekar, Tamás Ágh, Maria Malmenäs, Amit D Raval, Bryan M Bennett, Bijan J Borah, David S Hutchins, Elizabeth Manias, Allison F Williams, Mickaël Hiligsmann, Adina Turcu-Stiolica, John E Zeber, Lusine Abrahamyan, Thomas J Bunz, Andrew M Peterson
BACKGROUND: A broad literature base exists for measuring medication adherence to monotherapeutic regimens, but publications are less extensive for measuring adherence to multiple medications. OBJECTIVES: To identify and characterize the multiple medication adherence (MMA) methods used in the literature. METHODS: A literature search was conducted using PubMed, PsycINFO, the International Pharmaceutical Abstracts, the Cumulative Index to Nursing and Allied Health Literature and the Cochrane Library databases on methods used to measure MMA published between January 1973 and May 2015...
February 2019: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://read.qxmd.com/read/30661640/economic-evaluation-for-health-investments-en-route-to-universal-health-coverage-cost-benefit-analysis-or-cost-effectiveness-analysis
#18
Anthony J Culyer, Kalipso Chalkidou
BACKGROUND: It is an unresolved issue as to whether cost-benefit analysis (CBA) or cost-effectiveness analysis (CEA) is the preferable analytical toolkit for use in health technology assessment (HTA). The distinction between the two and an expressed preference for CEA go back at least to 1980 in the USA and, most recently, a Harvard-based group has been reappraising the case for CBA. OBJECTIVES: This article seeks to answer the question: would the use of cost-benefit analysis rather than the more usual cost-effectiveness analysis be an improvement, specifically in appraising health and health-related investments in low and middle-income countries (LMICs) as they transition to Universal Health Coverage?...
January 2019: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://read.qxmd.com/read/30661639/assessing-emotional-functioning-with-increased-power-relative-validity-of-a-customized-eortc-short-form-in-the-international-action-trial
#19
Lea J Jabbarian, Mogens Groenvold, Morten Aa Petersen, Caroline Arnfeldt Christensen, Luc Deliens, Agnes van der Heide, Marijke C Kars, Guido Miccinesi, Sheila Payne, Andrew Wilcock, Ida J Korfage
OBJECTIVES: There is a need to improve the assessment of emotional functioning (EF). In the international Advance Care Planning: an Innovative Palliative Care Intervention to Improve Quality of Life in Cancer Patients - a Multi-Centre Cluster Randomized Clinical Trial (ACTION) trial involving patients with advanced cancer, EF was assessed by a customized 10-item short form (EF10). The EF10 is based on the European Organisation for Research and Treatment of Cancer (EORTC) EF item bank and has the potential for greater precision than the common EORTC Quality of Life Questionnaire Core 30 four-item scale (EF4)...
January 2019: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://read.qxmd.com/read/30661638/alternative-weighting-approaches-for-anchored-matching-adjusted-indirect-comparisons-via-a-common-comparator
#20
Helmut Petto, Zbigniew Kadziola, Alan Brnabic, Daniel Saure, Mark Belger
BACKGROUND: Adjusted indirect comparisons (anchored via a common comparator) are an integral part of health technology assessment. These methods are challenged when differences between studies exist, including inclusion/exclusion criteria, outcome definitions, patient characteristics, as well as ensuring the choice of a common comparator. OBJECTIVES: Matching-adjusted indirect comparison (MAIC) can address these challenges, but the appropriate application of MAICs is uncertain...
January 2019: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
journal
journal
34615
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"